chemotherapy-induced nausea and vomiting

Also found in: Dictionary, Thesaurus, Encyclopedia.

chemotherapy-induced nausea and vomiting (CINV)

nausea and vomiting occurring as a reaction to chemotherapeutic agents.

chemotherapy-induced emesis

An adverse effect of many chemotherapeutics, which is usually self-limited and rarely life-threatening.
Highly emetogenic
Cisplatin, carmustine, dacarbazine, dactinomycin, mechlorethamine (nitrogen mustard), streptozocin.
Moderately emetogenic
Azacitidine, arparginase, carboplatin, cyclophosphamide, doxorubicin, mitomycin.
Dopamine (D2 high-dose metoclopramide), serotonin (5-HT3 receptor antagonists—e.g., ondansetron),

chemotherapy-induced nausea and vomiting

Vomiting that occurs after the administration of drugs used to treat cancer. Although its causes are complex, it appears to result from both direct irritation of the gastrointestinal tract by cytotoxic drugs, and the release of chemical mediators, such as 5-hydroxytryptamine (5-HT), from the gastrointestinal tract. 5-HT antagonists are among the most effective treatments. Dopaminergic effects in the central nervous system are also involved in chemotherapy-induced nausea and vomiting, and drugs that antagonize these effects, such as phenothiazines and other neuroleptics, can be used to treat the syndrome. Endocannabinoid drugs, corticosteroids (such as dexamethasone), antianxiety drugs (such as lorazepam) also have selected uses. Drugs that block receptors for neurokinins (such as aprepitant) are esp. effective in treating emesis that occurs more than 24 hours after chemotherapy.
References in periodicals archive ?
Chemotherapy-induced Nausea and Vomiting (CINV) can be defined as acute CINV, delayed CINV or anticipatory CINV.
Of four treatments available in the United States for chemotherapy-induced nausea and vomiting, ondansetron (Zofran, marketed by GlaxoSmithKline Inc.
Chemotherapy-induced nausea and vomiting is reportedly a debilitating, yet often preventable, side effect of chemotherapy.
L) revealed on Thursday that it has entered into an agreement to acquire Zuplenz (ondansetron) for emetogenic chemotherapy-induced nausea and vomiting from Galena Biopharma (NasdaqCM:GALE) for a total up front consideration of USD3.
M2 EQUITYBITES-September 21, 2015-Heron Therapeutics' NDA resubmission for SUSTO Injection extended release accepted by the US FDA for review for prevention of acute and delayed chemotherapy-induced nausea and vomiting
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) said on Monday that it has resubmitted its New Drug Application (NDA) for SUSTOL for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) regimens, to the US Food and Drug Administration (FDA).
Full browser ?